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ABSTRACT
The identification of activation pathways linked to antitumor T-cell polyfunctionality in long surviving
patients is of great relevance in the new era of immunotherapy. We have recently reported that
dacarbazine (DTIC) injected one day before peptide-vaccination plus IFN-a improves the antitumor lytic
activity and enlarges the repertoire of Melan-A-specific T-cell clones, as compared with vaccination alone,
impacting the overall survival of melanoma patients. To identify the mechanisms responsible for this
improvement of the immune response, we have analyzed the endogenous and treatment-induced
antigen (Ag)-specific response in a panel of Melan-A-specific CD8C T-cell clones in terms of differentiation
phenotype, inhibitory receptor profile, polyfunctionality and AKT activation. Here, we show that Melan-
A-specific CD8C T cells isolated from patients treated with chemoimmunotherapy possess a late
differentiated phenotype as defined by the absence of CD28 and CD27 co-stimulatory molecules and high
levels of LAG-3, TIM-3 and PD-1 inhibitory receptors. Nevertheless, they show higher proliferative potential
and an improved antitumor polyfunctional effector profile in terms of co-production of TNF-a, IFNg and
Granzyme-B (GrB) compared with cells derived from patients treated with vaccination alone.
Polyfunctionality is dependent on an active AKT signaling related to the engagement of the co-stimulatory
molecule ICOS. We suggest that this phenotypic and functional signature is dictated by a fine-tuned
balance between TCR triggering, AKT activation, co-stimulatory and inhibitory signals induced by
chemoimmunotherapy and may be associated with antitumor T cells able to protect patients from tumor
recurrence.
Abbreviations: Ag, antigen; APCs, antigen presenting cells; CTL, cytotoxic T lymphocyte; DTIC, dacarbazine; EC50,
half-maximal lysis; GrB, granzyme-B; ICOS, inducible costimulator; ICS, intracellular staining; IFN, interferon; iMFI,
integrated mean fluorescence intensity; KLRG1, killer cell lectin-like receptor G1; LAG-3, lymphocyte-activation gene
3; Melan-A, melanoma antigen A; PBMC, peripheral blood mononuclear cells; PD-1, Programmed death-1; PD-L1,
Programmed death-ligand 1; PHA, phytohemagglutinin; PI3K, phosphatidylinositol 3-kinase; pt, patient; TCR, T cell
receptor; TIM-3, T-cell immunoglobulin and Mucin Domain-3; TNF, tumor necrosis factor
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Introduction
Harnessing the T-cell response has proven to be a success-
ful strategy in order to prevent tumor relapse, as recently
reported for melanoma patients treated with combined che-
moimmunotherapy.1,2 Yet the mechanisms responsible for
drug-induced activation of antitumor immune response
remain to be elucidated, then understanding the complex
regulation of treatment-driven T-cell response is critical for
the design of effective combined therapies including cancer
vaccines.
T-cell response is a finely regulated process involving the
balance between Ag-specific T-cell receptor (TCR) activation
and co-stimulatory as well as inhibitory signals.3,4 The co-stim-
ulatory molecule CD28 plays a pivotal role during naive and
memory T-cell activation by inducing IL-2 production and pro-
moting proliferation,5,6 while CD27 is critical for the control of
TCR activation level and T-cell survival.7,8 The pattern of
CD28 and CD27 expression provides a characterization of
CD8C T-cell differentiation stage, with early differentiated cells
being CD28C/CD27C while intermediate and late differentiated
CONTACT Paola Nistico nistico@ifo.it.
Supplemental data for this article can be accessed on the publisher’s website.
*O.F. and B.P. contributed equally to this work.
Published with license by Taylor & Francis Group, LLC © Ornella Franzese, Belinda Palermo, Cosmo Di Donna, Isabella Sperduti, Virginia Ferraresi, Helena Stabile, Angela
Gismondi, Angela Santoni, and Paola Nistico.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/),
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the
named author(s) have been asserted.
ONCOIMMUNOLOGY
2016, VOL. 5, NO. 5, e1114203 (15 pages)
http://dx.doi.org/10.1080/2162402X.2015.1114203
T cells displaying a CD28¡/CD27C and CD28¡/CD27¡ pheno-
type, respectively.9,10 Inducible T-cell co-stimulator (ICOS),
another CD28 family member, has been reported to possess
partial functional redundancy in CD8CCD28¡ T cell co-stimu-
lation.11,12 Unlike CD28, which is constitutively expressed on T
cells, ICOS is expressed only after activation, and its deficient
expression has been associated with extensive T-cell dysfunc-
tion,13 a reduced memory T-cell compartment and imbalance
between effector and regulatory cells.14-16
As T cells progress toward terminal differentiation, they
upregulate the expression of co-inhibitory receptors, such as
Lymphocyte-activation gene 3 (LAG-3), T-cell immunoglobu-
lin and Mucin Domain-3 (TIM-3) and Programmed death-1
(PD-1), often in association with an exhausted phenotype and
decreased functionality,17-19 both features playing a key func-
tion in tumor-induced immune suppression.4 Besides their
inhibitory role, the expression of these molecules have recently
been observed in highly melanoma-reactive and clonally
expanded CD8C T lymphocytes20 and in activated T cells with-
out impairment of cytokine production.21,22 In particular, PD-1
has been suggested to be linked likely to a T-cell differentiation
status rather than to exhaustion.23
Among the mechanisms by which PD-1 has been reported
to inhibit T-cell activation, there is the suppression of the phos-
phatidylinositol 3-kinase (PI3K)/AKT signaling pathway and
the prevention of the CD28-mediated activation.24 PI3K/AKT
signaling pathway plays a key role in the survival and activation
of T cells25,26 where it is activated by TCR stimulation in con-
cert with co-stimulatory molecules, such as CD28 and ICOS as
well as cytokine receptor engagement.27 As T cells progress
toward differentiation and aging, they lose the ability to activate
AKT in parallel with the loss of CD28 co-stimulatory mole-
cule.12,28 Notably, the AKT pathway is critical for the control of
many aspects of the CD8C T-cell response including the effec-
tor versus memory fate.27,29
A combination of DNA alkylating agent DTIC plus peptide-
vaccination and interferon (IFN)-a as adjuvant, has been
reported to induce a diversification of the melanoma antigen A
(Melan-A)-specific TCR repertoire with potent antitumor
activity and significant clinical benefit in the prevention of mel-
anoma relapse.1,2 To identify immune parameters and path-
ways underlying the clinical advantage observed in patients
treated with combined therapy, we have performed an exten-
sive analysis of a panel of Melan-A-specific T-cell clones iso-
lated before and after treatments.
Melan-A-specific CD8C T cells derived from patients treated
with combined therapy showed an improved antitumor poly-
functional profile, a hallmark of protective immunity against
viruses and cancer,30-32 compared with those treated with vacci-
nation alone. These polyfunctional highly-reactive Melan-A-spe-
cific T cells displayed the highest expression of PD-1 molecule,
suggesting that in our settings, this molecule is not associated
with T-cell disfunctionality and impairment of cytokine produc-
tion. This functional effector profile was dependent on an active
AKT signaling pathway despite the late differentiated phenotype
of T cells, as defined by the absence of CD28 and CD27 co-stim-
ulatory molecules, and was related to the engagement of ICOS.
Of clinical relevance, this activation pathway was found only in
patients who benefit from chemoimmunotherapy treatment.
Results
Differentiation phenotype of Melan-A-specific CD8C T cells
and improved polyfunctional activity induced by DTIC plus
peptide-vaccination
DTIC plus peptide-vaccine combination (Arm2) has been
shown to improve the antitumor lytic activity of Melan-A-spe-
cific T-cell clones, as compared with vaccination alone (Arm1)
and to impact the overall survival of melanoma patients.1,2
First, in order to identify the mechanisms underlying the above
functional differences elicited by the chemoimmunotherapy, we
evaluated the differentiation phenotype and the multifunctional
profile of a number of Melan-A-specific CD8C T clones isolated
from different patients before and after treatment. The phenotypic
and functional characterization of CD8C T cells was performed
between the first and fourth round of stimulation with irradiated
antigen-presenting cells (APCs) plus phytohemagglutinin (PHA),
with overlapping results for each clone. The clinical characteristics
of the patients, the phenotype of T-cell clones (nD 66) analyzed in
this study and, when available, the TCR clonotype2 are described in
Table 1. Naturally occurringMelan-A-specific T cells isolated from
patients before therapy (PRE) showed a heterogeneous level of dif-
ferentiation based on the expression of CD28 and/or CD27, while
those isolated after both treatments (POST)were prevalently highly
differentiated effector memory (CD28¡CD27¡CCR7¡CD45RA¡,
Table 1).
Then we investigated the T-cell functional profile in terms of
co-production of tumor necrosis factor (TNF)-a, IFNg and GrB,
in response to HLA-A2C PD-L1C Melan-AC (MelC) melanoma
cell lines. Fig. 1A shows simultaneous intracellular staining (ICS)
for TNF-a, IFNg and GrB production of representative clones
(upper panel) and the quantification of the different possible com-
binations (lower panel). Fig. 1B shows pooled results from Melan-
A-specific T cells (n D 14 from Arm1, n D 27 from Arm2),
obtained by analyzing both the percentage of positive cells and the
integrated mean fluorescence intensity (iMFI), the latter a metric
that combines the relative amount of molecule produced (the
MFI) with the relative number of cells that make them (the per-
centage positive cells).33 The analysis of the single molecules evi-
denced a high production of both TNF-a and IFNg in clones
isolated before treatment (PRE). Of note, after therapy (POST)
clones isolated from Arm2 showed a significant increase (p <
0.0001) in the production of both these cytokines as compared
with Arm1 T cells (Fig. 1B). On the other hand, all clones analyzed
showed a high level of GrB production in the absence of specific
stimulation, which was maintained after exposure to tumor cells
irrespective of the treatment schedule, suggesting that in our set-
tings an increase of this molecule is not critical for the chemoim-
munotherapy-induced improvement of antitumor activity
(Figs. 1A and B). Stimulation of cells by unrelated HLA/Ag tumor
cell lines (Mel-) did not affect the baseline functional profile.
When we analyzed the polyfunctionality of T-cell clones
(Fig. 1C), a significant increase in molecule co-production was
observed in Arm2 patients, while clones from Arm1 showed an
impaired functional profile after the treatment. Finally, a strong
positive correlation was found by plotting polyfunctionality versus
antitumor lytic activity of each T-cell clone, as previously assessed2
(Fig. S1A), proving CD8C T-cell polyfunctionality as a reliable
marker for antitumor activity efficacy. On the other hand, the
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Table 1. Patients characteristics, clinical outcome and Melan-A-specific T-cell clones.
Clinical response Phenotype
Patient ID
Age
(y) Stage Arm Treatment RFS (y) OS (y)
Disease
recurrence Time
Clone
ID
Clonotype
ID
CCR7
(%)
CD45RA
(%)
CD28
(%)
CD27
(%)
PRE 5 nd 0 2 10 0
6 nd nd nd 0 nd
8 4 nd nd 0 0
9 2 0 0 0 15
17 5 nd nd 0 0
18 3 0 0 0 0
25 3 nd nd 0 0
32 nd 0 0 0 60
08 56 II 1 Peptide-
vaccination
alone
10C 10C No relapse POST 59 5 0 0 0 0
66 6 nd nd 0 0
71 4 0 0 0 0
90 5 0 0 10 0
95 7 nd nd 40 0
123 5 nd nd 0 0
132 7 nd nd 0 nd
145 5 0 0 0 0
22 22 III 1 Peptide-
vaccination
alone
0.7 2 Relapse PRE 10 14 nd nd 60 80
11 11 0 0 0 30
106 10 nd nd 10 30
POST 141 19 nd nd 10 30
205 20 nd nd 0 0
206 17 0 0 0 20
30 23 III 2 DTIC plus peptide-
vaccination
0.9 10C Relapse and
then
complete
response
PRE 23 29 nd nd 0 0
31 29 0 0 20 0
43 30 0 0 20 0
46 29 nd nd 0 35
POST 6 nd nd nd 0 nd
8 34 0 0 0 0
19 nd nd nd 0 nd
22 nd 0 0 40 0
43 nd 0 0 0 0
45 nd 0 0 0 0
46 nd nd nd 0 30
147 32 0 0 36 20
162 nd 0 0 0 0
171 nd 0 0 0 0
184 33 nd nd 0 nd
15 42 IV 2 DTIC plus peptide-
vaccination
10C 10C No relapse PRE 15 nd 0 0 0 0
19 nd 0 0 0 55
20 22 nd nd 0 nd
22 21 0 0 0 35
24 21 nd nd 0 0
30 21 0 0 0 80
38 21 0 15 0 60
50 nd nd nd 0 25
60 21 nd nd 0 0
81 21 0 0 10 40
POST 1 nd 0 0 0 0
3 25 nd nd 0 0
4 26 0 0 0 0
5 nd nd nd 0 0
12 nd nd nd 0 0
13 27 nd nd 0 nd
24 25 0 0 0 0
26 28 0 0 0 0
29 25 0 0 0 0
59 nd nd nd 0 0
99 nd 0 0 0 0
111 nd 0 0 0 0
09 46 III 2 DTIC plus peptide-
vaccination
10C 10C No relapse PRE 6 nd nd nd 0 10
POST 315 nd nd nd 0 0
331 nd 0 0 0 0
333 nd nd nd 0 0
370 nd nd nd 0 0
374 nd 0 0 0 0
377 nd 0 0 0 0
Age on enrollment.
Time of T-cell cloning.2
Identification number (ID) of each clonotype identified by TCR b-chain sequencing.2 RFS, relapse-free survival; OS, overall survival; nd, not determined.
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DTIC-associated functional improvement could not be ascribed to
T-cell avidity toward either the natural Melan-A26-35 or the analog
peptide used in our vaccine formulation (Melan-AA27L), as defined
by half-maximal lysis (EC50) (Figs S1B and C), in agreement with
our previous results and other studies.2,34
Combined chemoimmunotherapy activates the AKT
pathway in late differentiated T cells
In order to identify signaling pathways potentially activated by
DTIC plus vaccination and responsible for the increase in antitu-
mor polyfunctionality of T cells, we focused on AKT signaling,
which can favor the induction andmaintenance of cytotoxic T lym-
phocyte (CTL) effector molecules, while its inhibition causes the
loss of IFNg mRNA and prevents IFNg production.29
In CD8C T cells, AKT can be activated by TCR activation,
cytokines and co-stimulatory molecules.27 Conversely, the loss of
AKT enzymatic activity has been associated with the acquisition
of a highly differentiated phenotype characterized by the lack of
CD28 and CD27, critical molecules for T-cell activation and
markers for the classification of T-cell subsets at different stages
of differentiation.9,12 We analyzed AKT activation in terms of
phosphorylation of Ser473 (pSer473-AKT) in a number of
Melan-A specific clones (n D 26). CD8C T cells isolated before
the treatments displayed an early and intermediate level of differ-
entiation and showed pSer473-AKT expression (Table 1 and
Fig. 2). After therapy, all clones analyzed lacked CD28 and CD27
molecules, compatible with a late differentiated phenotype. Inter-
estingly, while cells isolated from Arm1 patients showed a nega-
tive or low levels of pSer473-AKT, all clones evaluated (n D 11)
from Arm2 patients displayed pSer473-AKT (Fig. 2) and down-
stream substrate target activation (i.e. Bclx, pSer2448mTOR, pp70,
Fig. S2). In parallel, the status of pSer473 AKT phosphorylation
was investigated by flow cytometry in a number of Melan-A-spe-
cific CD8C T cells. A representative staining for T-cell clones iso-
lated PRE and POST therapy from both Arms is shown in Fig. S3
and confirms the results obtained byWestern blot analysis.
These results indicate that the combination of DTIC plus
vaccination activates the AKT signaling pathway in CD28¡
CD27¡ late differentiated Melan-A-specific CD8C T-cell clones
with a highly polyfunctional profile.
Since AKT kinase can be activated by IL-2 and IL-15,26 we
evaluated a possible correspondence between the AKT activity
and the levels of IL-2/IL-15 receptor expression in our clones.
We observed a similar expression of the IL-2/IL-15 common
receptor b subunit (CD122) in all clones analyzed, while lower
levels of IL-2 a subunit (CD25) were observed in cells isolated
after therapy, irrespective of the treatment (Fig. S4A). The lack
of a critical role of IL-2/IL-2R was proved by the observation
that deprivation of IL-2 from culture medium only slightly
reduced AKT phosphorylation in T cells isolated from patients
after DTIC plus vaccination (Fig. S4B).
In order to evaluate whether this AKT activation was specifi-
cally related to Melan-A peptide-mediated stimulation, we also
performed biochemical and phenotypical analysis of CD8C T
cells specific for gp100, the other peptide employed in the vaccine
formulation. Unlike Melan-A-specific T cells, gp100-specific T
cells obtained from Arm2 patient 15, with an intermediate or late
differentiation profile, showed a low AKT activation pattern, as
shown in Fig. S5 for representative T cell clones. This result
strongly suggests that this AKT signaling pathway, identified only
in patients treated with DTIC before vaccination, is specifically
driven byMelan-A-elicited TCR activation.
DTIC plus peptide-vaccination modulates the pattern of
inhibitory molecules in Melan-A-specific CD8C T cells
Inhibitory receptors including LAG-3, TIM-3 and PD-1, are
generally associated with a chronically stimulated phenotype
in highly differentiated T cells,35 although the expression of
these receptors “per se” does not indicate that a T cell is
exhausted.23 Nevertheless, inhibitory molecules have been
shown to control Ser473-AKT phosphorylation in
CD8CCD28¡CD27¡ T cells.28,36 To investigate whether the
different vaccine-treatments influenced the balance between
the inhibitory receptor pattern, we studied the expression of
LAG-3, TIM-3 and PD-1 in relation to the AKT pathway in
a number of clones, either unstimulated or anti-CD3-acti-
vated. Representative plots of multiple staining and the rela-
tive gating strategy for molecule co-expression are shown in
Fig. 3A. In unstimulated T cells, the LAG-3 molecule was
undetectable or weakly expressed, whereas TIM-3 was
highly expressed in all clones analyzed, either PRE or POST
therapy. Differently, the expression of PD-1, absent in T-
cells isolated before the treatments, was induced only by the
combined therapy (p D 0.001; Figs. 3A and B). When T
cells were stimulated with anti-CD3 mAb, an increase in
LAG-3 and PD-1 molecules was observed irrespective of the
treatment (Fig. 3). Again, cells isolated after the combined
therapy showed the highest level of PD-1, also in terms of
co-expression with LAG-3 and TIM-3. Unexpectedly, we
found the highest expression of PD-1 along with activated
AKT in cells isolated from Arm2 patients, characterized by
an improved antitumor activity and polyfunctional profile
(Fig. 3C, green squares). When we measured PD-L1 in
clones isolated from both Arms, we found similar levels of
expression independent of the treatment (data not shown).
On the other hand, the high expression of inhibitory recep-
tors, and in particular PD-1, did not interfere with the T-
cell proliferative potential, as measured by iMFI for the pro-
liferation marker Ki-67, as shown in Fig. 4. Altogether these
data suggest that the high expression of inhibitory receptors
of Arm2 T-cell clones does not interfere with T-cell prolif-
erative potential and does not affect the chemoimmunother-
apy-induced AKT activation.
We then analyzed the expression of the killer cell lectin-like
receptor G1 (KLRG1), a marker of terminal differentiation,
that is associated with impaired proliferative potential37 by
inhibiting AKT phosphorylation.28 As shown in Fig. S6,
KLRG1 expression was not found in any of Melan-A specific
CD8C T cells analyzed.
Inhibition of AKT activation, but not PD-1 blockade,
reduces the antitumor activity of Melan-A-specific CD8C
T cells
The unexpected co-presence of high PD-1 levels along with
AKT activation in late differentiated polyfunctional T cells
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Figure 1. Melan-A-specific CD8C T cells exhibit an enhanced polyfunctional profile after chemoimmunotherapy. (A) Representative dot plot gating strategy of multicolor
intracellular staining for TNF-a (TNF), IFNg (IFN), and Granzyme-B (GrB) in Melan-A-specific CD8C T cells stimulated with HLA-A2C Melan-A-expressing (MelC) melanoma
cell line (top panel). The multicolor histograms in the bottom panel show the quantification of all possible combinations of molecule co-expression, evaluated in the
absence of stimulus (¡) or after 4 h stimulation with A2C/Melan-AC (MelC) or A2C/Melan-A¡ (Mel-) melanoma cell lines. (B–C) Pooled results from all T-cell clones evalu-
ated (n D 14 from two patients of Arm1, n D 27 from three patients of Arm2), isolated before (PRE) and after therapy (POST), analyzed as percentage of positive cells (%,
left) and integrated MFI (iMFI, right) (see Material and Methods for details). Data are displayed singularly (B) and simultaneously (C). Each dot represents the mean value
from two to four independent experiments performed with a single T-cell clone. The mean § SEM of each indicated sample group is shown. Polyfunctionality profile
(TNF-aCIFNgCGrBC) is also shown as box-and-whisker diagram, with 5–95 percentile. /^p  0.05, /^^p  0.01, /^^^p  0.001, /^^^^p  0.0001, Mann–
Whitney two-sample test () and two-tail Student’s test (^), respectively.
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isolated after DTIC plus vaccination, prompted us to further
explore the involvement of these pathways in T cell antitumor
activity.
First, we performed a time course blockade (1, 2 and 15 h) of
the AKT signaling pathway in highly polyfunctional CD8C T-
cell clones isolated after combined therapy, before stimulation
with Melan-A-expressing tumor cells. Blockade was performed
by pre-treatment with non-specific Ly294002 PI3K (PI3Ki) or
specific MK-2206 AKT (AKTi) inhibitors and then tumor-
induced production of IFNg was evaluated by ICS. Erk inhibi-
tor FR 180204 was used as internal control.
IFNg production was inhibited in CD8C T cells pre-incu-
bated either with LY 294002 (40%) or MK-2206 (70%) for 1 h.
Restoration to a basal IFNg level was observed when cells were
pre-treated with the inhibitors for 15 h before tumor recogni-
tion (Fig. 5A). Blockade with MK-2206 AKT specific inhibitor
determined a more durable inhibition of IFNg production
(60% with 2 h blockade) as compared with the non-specific
PI3K inhibitor. The inhibition of cytokine production mediated
by the AKT inhibitors is not due to a T cell-toxicity event, as
indicated by the restoration of IFNg production after 15 h of T
cell treatment. Based on these kinetic settings, blockade of
PI3K and AKT activation for 1 h before exposure to Melan-A-
expressing cell lines led to the inhibition of both TNF-a and
IFNg production in highly functional CD8C T-cell clones iso-
lated after combined therapy (Figs. 5B and C, for a representa-
tive clone out of three analyzed). GrB, which was expressed
also in unstimulated cells, was not affected by the blockade
(Fig. 5B). Fig. 5D shows the mean for the inhibition values
obtained in all the clones analyzed. Erk inhibitor FR 180204,
used as internal control, did not affect the production either of
TNF-a or IFNg. These results confirm a critical role for AKT
activation in the chemoimmunotherapy-induced functional
advantage in terms of polyfunctional profiling.
Noteworthy, the production of TNF-a, IFNg or GrB was not
affected by the inhibition of the PD-1 pathway, either by anti-
PD-1 or anti-PD-L1 specific mAbs in Melan-A-specific CD8C
T cells isolated after the combined therapy (Figs. 5B–D). On
the other hand, blockade of PD-1 pathway slightly enhanced
the cytokine production in cells from patients treated with vac-
cination alone (data not shown).
ICOS is involved in AKT activation induced by
chemoimmunotherapy
In order to identify T-cell co-stimulatory molecules potentially
responsible for the PI3-K/AKT activation observed in our pol-
yfunctional T cells, we investigated the role of ICOS which
Figure 2. Melan-A-specific CD8C T cells isolated after combined chemoimmunotherapy display pSer473-AKT expression unrelated to their differentiation stage. Analysis
of AKT activation by Western blot in terms of phosphorylation of Ser473 (pSer473-AKT) and total AKT expression tested on whole cell extracts of 1.5 £106 viable Melan-A
specific clones (n D 26), isolated before (PRE) and after treatment (POST) with vaccination alone (Arm1) or DTIC plus vaccination (Arm2), 18 h following activation by
plate-coated anti-CD3 mAb plus rIL-2. Gel loading control was performed analyzing b actin expression. The differentiation status (based on the expression of CD28 and/
or CD27 co-stimulatory molecules, see Table 1) for each clone is reported. Cells isolated from patients before the treatments evidence an expression of pSer473-AKT which
relates with the differentiation status. Cell clones isolated after therapy (POST) are late differentiated (defined by the lack CD28 and CD27 molecules). Cells isolated from
Arm1 (Arm1-POST) do not express pSer473-AKT according to their late differentiated profile, differently clones isolated from Arm2 patients (Arm2-POST) display a strong
pSer473-AKT expression. Densitometric quantification (OD) of protein bands was determined by NIH ImageJ software and expressed p-AKT/AKT ratios are expressed
either as numbers and columns.
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shares the CD28 motif of the cytoplasmic tail responsible for
the kinase activation. Differently from CD28 which is consti-
tutive, ICOS is induced following TCR stimulation14 and its
ligand (ICOS-L/B7H) is expressed by APC and human mela-
nomas.38-40 Flow-cytometric analysis performed following
48 h stimulation by anti-CD3 mAb, evidenced the highest lev-
els of the co-stimulatory molecule in clones isolated from
patients treated with the combined therapy (Fig. 6A). Of note,
a statistically significant correlation was found between high
levels of ICOS (cut-off > 30%) and p-AKT expression
(Fig. 6B).
Then, to confirm the contribution of ICOS in AKT activa-
tion induced by chemoimmunotherapy, we modulated this
pathway either by blocking with an anti-ICOS ligand mAb or
activating by an anti-ICOS agonist mAb. For the blockade
experiment, whole blood-isolated APC were pre-incubated with
anti-ICOS-L/B7H mAb for 15 h, co-cultured with the Melan-
A-specific CD8C T-cell clones expressing p-AKT and analyzed
by Western blot. AKT phosphorylation at Ser473 induced by
stimulation was reduced by the ICOS blockade of about 50%, as
evidenced in the representative immunoblotting of clone
Pt15.26, and not affected by the IgG isotype control (Fig. 6C,
left panel). Of relevance, the blockade of the pathway inhibited
the production of TNF-a, IFNg and GrB, as measured by ICS
(Fig. 6D, top panel). For the activation experiment, Melan-A-
specific CD8C T-cells were stimulated 24 h with anti-CD3 mAb
Figure 3. Melan-A-specific CD8C T-cell clones isolated after DTIC plus vaccination display the highest level of PD-1 inhibitory receptor expression. (A) Representative flow
cytometric analysis of multicolor staining, with the relative gating strategy, for simultaneous LAG-3 (L), TIM-3 (T) and PD-1 (P) expression. The multicolor histograms show
the quantification of all possible combinations of molecule co-expression, for representative clones isolated either before (PRE) or at the end (POST) of both treatments.
The staining was performed under basal cell culture conditions (¡) or after over-night activation by plate-bound anti-CD3 mAb (2 mg/mL) (C). (B) Comparison from
pooled data of inhibitory receptor profiles in PRE (black histograms) vs. POST (red histograms) treatment, displayed as single receptor expression, with (C) or without (¡)
anti-CD3 mAb activation. Each bar represents the mean percentage (§ SD) of inhibitory receptor expression of Melan-A-specific T-cell clones isolated from patients of
Arm1 (n D 2) and of Arm2 (n D 3), before (PRE, n D 6 for Arm1, n D 7 for Arm2) and after (POST, n D 7-8 for Arm1, n D 7–9 for Arm2) treatments. (C) The percentage of
single or simultaneous inhibitory receptor expression in T-cell clones isolated at the end of both treatments (POST), with (■) or without () anti-CD3 activation. Each dot
represents the mean value out of three–five independent experiments performed on a single T-cell clone. The mean § SEM of each indicated sample group is shown.
Black and green dots, clones negative or positive for pSer473-AKT, respectively, as assessed by Western blot analysis; gray dots, clones not tested for AKT phosphorylation.
/^p  0.05, /^^p  0.01, /^^^p  0.001, /^^^^p  0.0001, Mann–Whitney two-sample () test and two-tail Student’s test (^), respectively.
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or anti-CD3 plus anti-ICOS agonist. An increase of AKT phos-
phorylation and polyfunctional activity was induced by ICOS
co-stimulation (Fig. 6C, right panel and Fig. 6D, bottom panel,
respectively). As expected, the increase of polyfunctional activ-
ity by ICOS co-stimulation was higher in clones from Arm2
patients, which displayed the highest ICOS expression
(Fig. 6A). These results suggest a critical role for ICOS in con-
tributing to AKT activation and polyfunctionality in late differ-
entiated CD8C T cells isolated after chemoimmunotherapy.
Discussion
The identification of activation pathways linked to T-cell poly-
functionality against tumors, associated with clinical benefit, is
of great relevance in the new era of immunotherapy and com-
bined chemoimmunotherapy. Recently, we reported that
Melan-A-specific CD8C T cells isolated from long-term sur-
vival patients treated with DTIC injected in a tight window
before peptide-vaccination plus IFN-a, possess higher tumor
reactivity and an enlarged T-cell repertoire, compared to cells
isolated after vaccination alone.1,2
Here, we have explored the molecular mechanisms underly-
ing the antitumor functionality of these T cells. We found that
Melan-A-specific CD8C T cells isolated from patients treated
with chemoimmunotherapy, despite the late differentiation
profile, show the highest antitumor activity in terms of poly-
functionality that is dependent on the activation of the AKT
pathway and is associated with the engagement of ICOS, in the
presence of LAG-3, TIM-3 and PD-1 inhibitory receptors.
Melan-A-specific T-cell clones derived from patients treated
with the combined therapy, revealed a more potent antitumor
cytolytic profile in terms of polyfunctionality defined by the co-
production of TNF-a, IFNg and GrB, compared with cells
derived from patients treated with vaccination alone. Polyfunc-
tionality reflects the ability of individual T cells to perform mul-
tiple effector functions and is crucial for the protective
immunity against viruses and cancer.30-32 Polyfunctional CD8C
T cells producing several effector cytokines and molecules are
associated with the spontaneous resolution of primary acute
HCV41 and have been related to HIV-specific enlarged T-cell
repertoire.42,43 Similarly, polyfunctional T cells can be induced
in cancer patients after vaccination.44-46 In our study, the long
overall survival observed in patients treated with the combined
chemoimmunotherapy is in line with the concept that poly-
functional antitumor CD8C T cells mediate a stronger host
antitumor response and may thus prevent disease recurrence.
Furthermore, the less effective quality of T-cell responses evi-
denced in patients treated with vaccination alone suggests that
the schedule of combined therapy could have contributed to
the induction of protective polyfunctional T cells. Although to
our knowledge no data are available about a possible regulation
of human T-cell polyfunctionality by combined immunother-
apy, preconditioning chemotherapy with the alkylating agent
cyclophosphamide has been shown to promote the generation
of polyfunctional CD4C effector T cells in murine models.30
The generation of polyfunctional CD8C T cells in response to
vaccination, although associated with improved protective
immunity has not yet been fully linked to a T-cell differentiation
phenotype. In our setting, cells isolated after the treatments, in
particular those obtained after the combined therapy, display a
highly differentiated profile as defined by the CD45RA¡CCR7¡
phenotype and the lack of co-stimulatory molecules CD28 and
CD27. Among multiple extracellular pathways, AKT signaling
has been reported as a major player in the cell fate decision ver-
sus effector CD8C T cells29,47 and the magnitude of AKT activa-
tion drives the differentiation of T cells into terminal effectors or
memory cells.47 On the other hand, it has been shown that AKT
activation decreases as CD8C T cells progress toward differentia-
tion.12,28 Here, we have observed that combined immunother-
apy, differently from vaccination alone, results in increased
AKT phosphorylation in highly differentiated Melan-A-specific
CD28¡CD27¡ T cells. Of note, T-cell polyfunctionality elicited
by combined therapy was strictly dependent on AKT activation,
as demonstrated by blockade with selective inhibitors, in agree-
ment with previous studies showing the impairment of the IFNg
production induced by AKT inhibition and the induction of an
effector phenotype in the presence of an active AKT signaling
pathway.29,47 This AKT activation occurred only in Melan-A-
specific CD8C T cells and not in cells specific for gp100, the
other peptide used in the vaccine formulation, where the AKT
Figure 4. Proliferative potential of Melan-A-specific T-cell clones. Intracellular
staining for Ki-67 expression of CTL clones (n D 12) isolated before (PRE) and after
(POST) treatments from both Arms, performed 7 d after re-stimulation with allo-
genic irradiated PBMC, rIL-2 and PHA. Top panel: representative staining for each
indicated sample group with anti-Ki-67 (open histograms) or isotype (filled histo-
grams) mAbs, showing the presence of two positive cell populations with diverse
amounts of Ki-67 molecule expression (low and high). Bottom panel: magnitude of
low and high proliferating cells as measured by integrated mean fluorescence
intensity (iMFI), (see Material and Methods for details). Results are shown as mean
§ SD.
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phosphorylation was expressed according to their differentia-
tion profile, suggesting that the structure of the Ag/TCR com-
plex is critical for the activation of this pathway.
It has been recently reported that AKT inhibition induces
the generation of long-lived tumor-reactive memory T cells in
murine and human models.48-50 The results of Crompton’ and
Abu’s studies may differ from our results due to the long AKT
inhibition treatment (up to 30 d) performed in gp-100-specific
T cells. Similarly, Van der Waart study reports the possibility
of expanding CD28CCD27C CD8C T memory-like efficient
antitumor cells by inhibiting AKT signaling in naive precur-
sors. These apparently differing results can be ascribed to the
differentiation status of the CD8C T cells evaluated, i.e., late dif-
ferentiated CD28¡CD27¡ in our settings, and early memory-
like CD28CCD27C T cells in the study by van Der Waart. From
our data, although the mechanisms regulating the AKT
activation are still unclear, we can speculate that combined
therapy may favor an effector phenotype, with an improvement
of the proliferative potential as defined by Ki-67 expression, in
late differentiated Melan-A-specific CD8C T cells.
In the possible redundancy of co-stimulatory receptor
usage, ICOS is known to enhance T-cell activation when
CD28 expression is limited or absent.12,51 We found that
combination therapy induced the highest expression of
ICOS in Melan-A-specific CD8CCD28¡CD27¡ T cells with
the phosphorylation of AKT at Ser 473 partially dependent
on the engagement of the ICOS/ICOS-L pathway. This was
not related to the expression of receptors for IL-2 and IL-
15, cytokines known to be involved in the activation of the
AKT pathway,52 confirming previous studies showing that
ICOS, differently from CD28, impacts on proliferation
along with IFNg, but not IL-2 production.53 Deficiency in
Figure 5. AKT-dependent antitumor activity of highly polyfunctional tumor-specific CD8C T cells elicited by the combined chemoimmunotherapy. Modulation of TNF-a
(TNF), IFNg (IFN), and Granzyme-B (GrB) co-production by AKT or PD-1 blockade, in clones from Arm2 patient (Pt15). (A) Kinetic of IFNg production after AKT pathway
blockade, with a PI3K (Ly294002, PI3Ki) or AKT inhibitor molecule (MK-2206, AKTi). Figure shows the mean§ SD of three independent experiments performed on a repre-
sentative Arm2 Melan-A-specific T cell clone (Pt15.29) after specific recognition of Melan-A-expressing cell line (MelC). Results are shown as a percentage of IFNg produc-
tion (top panel) or as a percentage of inhibition with respect to the maximal baseline production (bottom panel). A specific Erk inhibitor (FR 180204) was used as internal
control. (B–C) Flow cytometry analysis of multicolor staining from a representative Melan-A-specific clone (Pt15.29), showing the single % of production (B) or the co-pro-
duction (C) of TNF-a, IFNg , and GrB in the presence (1 h) or in the absence of inhibitors. TNF-a and IFNg , but not GrB, are significantly reduced by the AKT blockade. PD-
1 blockade, by specific anti-PD1 (a-PD-1) or anti-PD-L1 (a-PD-L1) mAbs (18 h) does not affect the TNF-a, IFNg, and GrB production capability. (D) Pooled data from three
different T-cell clones (Pt15.3, Pt15.26, Pt15.29 ) showing the mean § SD of the % of inhibition evaluated under different blockade conditions, relative to baseline
production.
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ICOS expression has been associated with extensive T-cell
dysfunction and impaired memory T-cell compartment.54
Besides, this molecule has proven effective in the enhance-
ment of cytokine-mediated cell toxicity, in part by
increasing IFNg secretion.55 Of note, ICOS has been identi-
fied as a crucial player in the anti-melanoma effects of
CTLA-4 blockade56 and critically co-expressed with PD-1 as
a potential identifier of tumor-reactive cells.20
Figure 6. For figure legend, see page 11.
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Although inhibitory receptors have so far been considered to
mark terminally differentiated “exhausted” T cells,35 they have
recently been associated with the activation and differentiation
profile of T cells.23 PD-1 and KLRG1 have been shown to con-
tribute to the defect of AKT phosphorylation in highly differen-
tiated CD8C CD28¡ CD27¡T cells.28,36 Differently, the
activation of AKT we observed in Melan-A-specific clones iso-
lated after the chemoimmunotherapy was not the result of a
reduced expression of inhibitory receptors since high levels of
LAG-3, TIM-3 and PD-1 were found in all the clones analyzed,
with cells isolated after the combined therapy showing the
highest PD-1 expression. This phenotypic profile may be
instrumental for limiting the self-tissue damage, as supported
by the lack of autoimmune evidences in our patients. On the
other hand the co-expression of PD-1 and ICOS may represent
a rheostat in the control of highly reactive Ag-stimulated T
cells, as recently reported for PD-1.57 Our findings do not raise
doubts about the clinical usage of blocking inhibitory check-
points in the presence of T cells with such phenotype,4,58-60 as
the blockade of PD-1 does not impair the AKT-dependent pol-
yfunctionality. Rather these findings highlight the importance
of taking into account the status of T-cell activation and differ-
entiation in the selection of patients who can take advantage of
the inhibition of these pathways.
About other players potentially involved in this peculiar
activation of AKT in T cells pre-exposed to DTIC and sus-
tained by Melan-A-mediated expansion, we can speculate that
it can be the consequence of DNA damage events, as reported
for Temozolomide, the active DTIC metabolite.61 Further, we
cannot exclude that IFN-a, administrated locally in both treat-
ment Arms as adjuvant,62 may have contributed to the genera-
tion of polyfunctional Melan-A-specific CD8C T cells with an
activated AKT pathway.
Of clinical relevance patients who received DTIC plus vacci-
nation, although affected by III/IVa stage melanoma, are cur-
rently disease-free, after 10 y from the end of the treatment,
thus suggesting that AKT-dependent polyfunctional tumor-
reactive T cells, endowed with an enlarged Melan-A-specific
TCR repertoire,2 may protect from disease relapse.
Although we recognize that the study of a large number of
clones only partially resembles the “in vivo” scenario, the pres-
ent findings represent a critical contribution for the compre-
hension of the mechanisms underlying the advantages of
combined chemoimmunotherapy. We suggest that combina-
tion DTIC plus vaccination may induce a phenotypic and
functional signature dictated by a fine-tuned balance between
quality of Ag/TCR complex, co-stimulatory signals such as
ICOS, inhibitory checkpoints and AKT activation, associated
with antitumor T cells able to protect patients from tumor
recurrence. As far as new methodologies will improve immune
monitoring at single cell level, the analysis of the identified acti-
vated AKT pathway may represent a new biomarker of T-cell
activation and responsiveness in the course of immunomodu-
lating cancer therapies.
Material and Methods
Patients, cell lines and T-cell clones
Treatment of melanoma patients enrolled in Arm1 and
Arm2 vaccination protocol has been described.1 Pt.08 and
Pt.22 were vaccinated with Melan-A (A27L) and gp100
(210M) peptides plus IFN-a (Arm1); Pt.09, Pt.15 and
Pt.30 received the DTIC one day before the same vaccina-
tion schedule (Arm2). Patients were followed for disease
progression by a total body CT scan periodically. T2 cell
lines were purchased from the American Type Culture
Collection. Melanoma cell lines Mel1 (HLA-A2¡/Melan-
AC, not shown), Mel2 (HLA-A2C/Melan-A¡, referred as
Mel-) and Mel3 and Mel4 (HLA-A2C/Melan-AC, referred
as MelC) were kindly provided by Dr A. Anichini (Fonda-
zione IRCCS Istituto Nazionale dei Tumori, Milan, Italy).
Melanoma cell lines were isolated from surgical specimens
of tumors of patients admitted to Fondazione IRCCS Isti-
tuto Nazionale dei Tumori, Milan. All lesions were histo-
logically confirmed to be cutaneous malignant melanomas.
Molecular and biological characterization of these cell lines
has been reported previously.63 Melanoma cell lines were
periodically checked for the expression of a panel of tumor
associated Ags (i.e. BRAF V600E, MITF, Tyrosinase,
Melan-A, gp100, MAGE) by intracellular flow cytometry
and Western blot analysis. Cell lines were periodically
checked (no more than 2 mo from the assays) morphologi-
cally, and tested by growth curve analysis by 3H-Thymi-
dine incorporation assay and Mycoplasma detection.
Melan-A-specific and gp100-specific T-cell clones were
generated by limiting dilution from presensitized Ag-spe-
cific T-cell lines as described2 and periodically restimulated
(every 3 weeks) in RPMI 1640 medium supplemented with
10% human serum (noncommercial, prepared from healthy
Figure 6. (see previous page) ICOS is upregulated in Melan-A-specific CD8C T cells isolated after combined therapy and is involved in chemoimmunotherapy-induced AKT
activation. (A) Top panel shows representative staining with anti-ICOS (open histogram) or isotype (filled histogram) mAbs, in two T-cell clones isolated from Arm1
(Pt08.90) and Arm2 (Pt15.26) patients after the treatments (POST). Bottom panel shows pooled data of ICOS expression in Melan-A-specific T-cell clones (n D 15 from
two patients of Arm1, n D 18 from three patients of Arm2), isolated before (PRE) and after therapy (POST). Cells were stained after 48 h stimulation with plate-bound
anti-CD3 mAb (2 mg/mL) plus rIL-2 and shown in both scatter-plot graph and box-and-whisker diagram, with 5–95 percentile. Each dot represents the mean value out of
three–five independent experiments. The mean§ SEM of each group is shown. (B) Correlation between p-AKT and ICOS expression. T-cell clones isolated after both treat-
ments were grouped according to pSerAKT expression levels and the percentage of ICOSC cells (bottom panel) and shows higher expression of ICOS in AKThigh T cells. Top
panel, percentage of clones with ICOS levels > 30% cut-off in p-AKTneg/low versus p-AKThigh groups. p value was calculated with one-tail Fisher’s exact test. /^p  0.05,
/^^p  0.01, /^^^p  0.001, Mann–Whitney two-sample test () and two-tail Student’s test (^), respectively. (C) Left panel: effect of ICOS blockade on AKT activa-
tion (p-Ser473-AKT) tested in a representative Melan-A specific T-cell clone (Arm2, Pt15.26, POST), following activation by irradiated PBMC-derived APCs plus rIL-2 (¡).
Blockade of ICOS engagement with anti-ICOS-L (ICOSLi) mAb (10 mg/mL) induced a marked downregulation of p-AKT. Right panel: effect of ICOS engagement on AKT
activation (p-Ser473-AKT) tested in a representative Melan-A specific T-cell clone (Arm2, Pt15.111, POST), following activation by anti-CD3 mAb (¡). The anti-ICOS-agonist
(ICOSa) mAb (12.5 mg/mL) induced upregulation of p-AKT. Gel loading control is represented by total AKT expression. Densitometric quantification of protein bands was
determined by NIH ImageJ software. Columns show the mean § SD of p-AKT/AKT ratios (OD) from two independent experiments. (D) Top panel: bars represent the
mean % (§ SD) of TNF-a, IFNg and GrB inhibition by ICOS blockade from two experiments performed on Pt15.26 T cell clone (representative of three different T-cell
clones tested). Bottom panel: bars represent the mean % (§ SD) of the increased polyfunctional activity induced by ICOS co-stimulation, as calculated with respect to the
isotype control mAb.
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donors), 1 mg/mL PHA (Roches, 11082132001), 25 U/mL
rIL-2 (Roches, 11147528001), and 1 £ 106/mL irradiated
allogenic peripheral blood mononuclear cells (PBMC) as
feeder cells. T-cell clones were used 13–15 d after PHA-
stimulation.
Antibodies and flow cytometry
Cell surface-staining was performed using various combina-
tions of the following Abs: PE-Cy5-CD27 (Beckman Coulter,
0826607107), FITC-CD45RA (BD Pharmigen, 335039), PE-
Cy7-CCR7 (BD Pharmigen, 557648), PE-CD25 (Miltenyi Bio-
tec, 130-091-024), PE-IL-2/IL15Rb (CD122, BD Pharmigen,
554525), PE-Cy7-PD-1 (BD Pharmigen, 561272), PE-Cy7-PD-
L1 (CD274, BD Pharmigen, 558017), PE-TIM3 (R&D Systems,
FAB2365P), FITC-LAG3 (Adipogen, Inc., AG-20B-0012F),
polyclonal-KLRG1 (Sigma-Aldrich, SAB1400378), PE-ICOS
(BD Pharmigen, 557802). The CD28 hybridoma CD28.2
(IgG1) was provided by Dr D. Olive (Inserm UMR). ICS was
performed with the following mAbs: PerCP-Cy5.5-TNF-a (BD
Pharmigen, 560679), PE-Cy7-IFNg (BD Pharmigen, 557643),
Alexa Fluor647-GrB (BD Pharmigen, 560212) and Ki-67
(Dako, M7240). For CD28, KLRG1 and Ki-67 staining, a sec-
ondary PE-labeled anti-mouse antibody (Dako, R0439) was
used. Ag-specificity of T-cell clones was periodically tested by
the use of FITC-CD8C (Miltenyi Biotec, 130-080-601) and PE-
Melan-A/gp100 tetramers (Beckman Coulter, 082T01008/
082T01012) as described.1 The surface staining was performed
for 30 min at 4C. When possible, dead cells were excluded
using propidium iodide staining (MP Biomedicals, 195458).
When required, stimulation with plate-bound anti-CD3 mAb
(2 mg/mL) (CBT3 IgG2a,64) was performed as indicated. For
ICS of p-AKT, T-cell clones were cultured in RPMI medium
supplemented with 1% HS for 2 h, and stimulated by plate-
bound anti-CD3 mAb for 2 h at 37C. The staining was per-
formed after fixation with 1.6% paraformaldehyde and permea-
bilization with 80% methanol by the use of Alexa Fluor 647
anti-AKT pS473 (BD Pharmigen, 561670). Cells were immedi-
ately acquired on BD FACSCanto II (BD Bioscience) and ana-
lyzed using FlowJo 9.2.3 (TreeStar), FACSDiva and CellQuest
software (BD). For receptor blocking experiments, the follow-
ing functional grade purified mAbs purchased from eBioscience
were used: anti-PD1 (IgG1, 16-9989), anti-PD-L1 (IgG1, 16-
5983), anti-ICOSL (IgG1, 16-5889) and control Isotype (IgG1,
16-4714). The blockade was performed by incubation of T cells
and/or target cells overnight with the corresponding blocking
antibody (10 mg/mL) or with the control Isotype. Then cells
were washed and co-cultured for the indicated time. For ICOS
activation experiments, cells were incubated for 24 h with
plate-bound functional grade anti-ICOS agonist mAb (IgG1,
eBioscience, 16-9948-82 ) (12.5 mg/mL) in the presence of anti-
CD3, before polyfunctional analysis. For some experiments, the
magnitude of staining was measured as iMFI, a metric that
combines the relative amount of molecule produced (the MFI)
with the relative number of cells that make them (the percent-
age positive cells).33 iMFI is computed by multiplying the per-
centage with the MFI of positive cells and reflects the total
functional response of a population.
TNF-a, IFNg, GrB production and cytotoxicity assay
For ICS production, Melan-A-specific T-cell clones were co-
cultured with related (MelC) or unrelated (Mel-) HLA/Ag
melanoma cell lines, for 4–5 h at 37C in the presence of the
protein transport inhibitor GolgiStop (BD, 554724). T-cell
clones were collected, washed with PBS, fixed using 2% paraf-
ormaldeide (15 min on ice) and then permeabilized by 5%
FCS, 0,5% Saponine in PBS (20 min at RT). Cells were then
incubated for 30 min at RT with PerCP-Cy5.5-TNF-a, PE-
Cy7-IFNg and Alexa Fluor647-GrB mAbs. The AKT signaling
pathway blockade was performed by pre-incubating T-cell
clones with 30 mM PI3K inhibitor molecule (Ly294002, Cell
Signaling Technology, 9901) or with 5 mM AKT inhibitor
molecule (MK-2206, Merck Pipeline, HY-10358) for 30 min,
1 h, 2 h or 15 h, as indicated. An Erk inhibitor (FR 180204,
Santa Cruz Biotechnology, SC203945) was used as internal
control. PD-1 and ICOS pathway blockade/activation were
performed as described above. Lytic activity and fine Ag rec-
ognition were assessed in a standard 4 h 51Cr release assay as
described.2 Briefly, T2 cells, Mel1, Mel2, Mel3 and Mel4 mela-
noma cell lines were used as target cells and cytotoxicity
assays were performed by incubating 51Cr-labeled target cells
with effector cells at an E:T ratios of 20:1. Fine Ag specificity
analysis measured pulsing T2 target cells with decreasing con-
centration of natural (Melan-A26-35), analog (Melan-AA27L) or
irrelevant gp100 peptides. The percentage of specific lysis was
calculated as follows: 100 £ (experimental release¡spontane-
ous release)/(total release¡spontaneous release).
Western blot analysis
T-cell clones were activated overnight by plate-bound anti-
CD3 mAb, in complete RPMI medium supplemented with
10% HS, with or without 25 U/mL rIL-2. Whole cell
extracts were obtained by lysis in 10% glycerol, 0.1% SDS,
0.5% DOC, 1% NP-40 in PBS. Lysates from 1.5 £ 106 cells
were separated on 10 % sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis gels and transferred to Hybond-P
membranes (Amersham Pharmacia Biotech, Piscataway,
NJ). Membranes were then probed with anti p-AKT (Ser
473, Cell Signaling, 4060S), AKT1 (Cell Signaling, 2938S),
Bclx (Cell Signaling, 2762), and pSer2448mTOR (Cell Signal-
ing, 2971) Abs, following the instructions provided by the
manufacturer. b-actin Ab (Cell Signaling, 3700S) was used
as loading control. Analysis was performed using the ECL
Prime Western detection kit (Amersham Pharmacia Bio-
tech, RPN 2236). X-ray films were scanned by HP Scanjet
5470 and processed by Corel Photo Paint 12. Densitometric
quantification of protein bands was determined by NIH
ImageJ software. For blocking experiments, Melan-A-spe-
cific CD8C T-cell clones, previously pre-incubated overnight
or not with anti-ICOS-L mAb, were stimulated in the pres-
ence of whole blood-APCs, and then analyzed for pSer473-
AKT as described above. For ICOS activation experiments,
cells were incubated for 24 h with plate-bound functional
grade anti-ICOS agonist mAb (12.5 mg/mL) in the presence
of anti-CD3, before pSer473-AKT Western blot analysis.
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Statistical analysis
Values are reported as mean § SEM/SD or median (range). As
evaluated in a similar study,65 the comparison between groups
was performed with a Mann–Whitney two-sample test,
unpaired Student’s t-test or Fisher’s Exact test, when appropri-
ate. The correlation analysis was performed with Spearman
and Pearson test. p value  0.05 was considered significant. Sta-
tistical analyses were carried out using SPSS software (SPSS ver-
sion 21, SPSS Inc., Chicago, IL, USA).
Disclosure of potential conflicts of interest
No potential conflicts of interest were disclosed.
Acknowledgments
The authors thank the patients for study participation and blood donation.
They are grateful to Dr F. Di Modugno for continuous helpful discussion.
M.V. Sarcone, N. Gualtieri, M Panetta are acknowledged for the technical
assistance. A particular thanks to A Soriani and M. L. Foddai for their con-
tinuous collaboration.
References
1. Nistico P, Capone I, Palermo B, Del Bello D, Ferraresi V, Moschella F,
Arico E, Valentini M, Bracci L, Cognetti F et al. Chemotherapy enhan-
ces vaccine-induced antitumor immunity in melanoma patients. Int J
Cancer 2009; 124:130-9; PMID:18839429; http://dx.doi.org/10.1002/
ijc.23886
2. Palermo B, Del Bello D, Sottini A, Serana F, Ghidini C, Gualtieri N,
Ferraresi V, Catricala C, Belardelli F, Proietti E et al. Dacarbazine
treatment before peptide vaccination enlarges T-cell repertoire diver-
sity of melan-a-specific, tumor-reactive CTL in melanoma patients.
Cancer Res 2010; 70:7084-92; PMID:20823160; http://dx.doi.org/
10.1158/0008-5472.CAN-10-1326
3. Frauwirth KA, Thompson CB. Activation and inhibition of lympho-
cytes by costimulation. J Clin Invest 2002; 109:295-299; PMID:
11827987; http://dx.doi.org/10.1172/JCI0214941
4. Pardoll DM. The blockade of immune checkpoints in cancer immu-
notherapy. Nat Rev Cancer 2012; 12:252-64; PMID:22437870; http://
dx.doi.org/10.1038/nrc3239
5. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell
costimulation. Annu Rev Immunol 1996; 14:233-58; PMID:8717514;
http://dx.doi.org/10.1146/annurev.immunol.14.1.233
6. Acuto O, Michel F. CD28-mediated co-stimulation: a quantitative
support for TCR signalling. Nat Rev Immunol 2003; 3:939-51;
PMID:14647476; http://dx.doi.org/10.1038/nri1248
7. Agematsu K, Kobata T, Sugita K, Freeman GJ, Beckmann MP,
Schlossman SF, Morimoto C. Role of CD27 in T cell immune
response. Analysis by recombinant soluble CD27. J Immunol 1994;
153:1421-9; PMID:8046222
8. Denoeud J1, Moser M. Role of CD27/CD70 pathway of activation in
immunity and tolerance. J Leukoc Biol 2011; 89:195-203;
PMID:20699361; http://dx.doi.org/10.1189/jlb.0610351
9. Appay V, Dunbar PR, Callan M, Klenerman P, Gillespie GM, Papagno
L, Ogg GS, King A, Lechner F, Spina CA et al. Memory CD8C T cells
vary in differentiation phenotype in different persistent virus infec-
tions. Nat Med 2002; 8:379-85; PMID:11927944; http://dx.doi.org/
10.1038/nm0402-379
10. Plunkett FJ, Franzese O, Belaramani LL, Fletcher JM, Gilmour KC,
Sharifi R, Khan N, Hislop AD, Cara A, Salmon M et al. The impact of
telomere erosion on memory CD8C T cells in patients with X-linked
lymphoproliferative syndrome. Mech Ageing Dev 2005; 126:855-65;
PMID:15992610; http://dx.doi.org/10.1016/j.mad.2005.03.006
11. Kopf M, Coyle AJ, Schmitz N, Barner M, Oxenius A, Gallimore
A, Gutierrez-Ramos JC, Bachmann MF. Inducible costimulator
protein (ICOS) controls T helper cell subset polarization after
virus and parasite infection. J Exp Med 2000; 192:53-61;
PMID:10880526
12. Plunkett FJ, Franzese O, Finney HM, Fletcher JM, Belaramani LL,
Salmon M, Dokal I, Webster D, Lawson AD, Akbar AN. The loss of
telomerase activity in highly differentiated CD8CCD28-CD27- T cells
is associated with decreased Akt (Ser473) phosphorylation. J Immunol
2007; 178:7710-9; PMID:17548608; http://dx.doi.org/10.4049/
jimmunol.178.12.7710
13. Dong C, Juedes AE, Temann UA, Shresta S, Allison JP, Ruddle NH,
Flavell RA. ICOS co-stimulatory receptor is essential for T-cell activa-
tion and function. Nature 2001; 409:97-101; PMID:11343121; http://
dx.doi.org/10.1038/35051100
14. Hutloff A, Dittrich AM, Beier KC, Eljaschewitsch B, Kraft R, Ana-
gnostopoulos I, Kroczek RA. ICOS is an inducible T-cell co-stimulator
structurally and functionally related to CD28. Nature 1999; 397:263-6;
PMID:9930702; http://dx.doi.org/10.1038/16717
15. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immu-
nol 2002; 2:116-26; PMID:11910893; http://dx.doi.org/10.1038/nri727
16. Takahashi N, Matsumoto K, Saito H, Nanki T, Miyasaka N, Kobata T,
Azuma M, Lee SK, Mizutani S, Morio T. Impaired CD4 and CD8
effector function and decreased memory T cell populations in ICOS-
deficient patients. J Immunol 2009; 182:5515-27; PMID:19380800;
http://dx.doi.org/10.4049/jimmunol.0803256
17. Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, Kalia V, Subra-
maniam S, Blattman JN, Barber DL, Ahmed R. Molecular signature of
CD8C T cell exhaustion during chronic viral infection. Immunity
2007; 27:670-84; PMID:17950003; http://dx.doi.org/10.1016/j.
immuni.2007.09.006
18. Shin H, Wherry EJ. CD8 T cell dysfunction during chronic viral infec-
tion. Curr Opin Immunol 2007; 19:408-15; PMID:17656078; http://
dx.doi.org/10.1016/j.coi.2007.06.004
19. McMahan RH, Golden-Mason L, Nishimura MI, McMahon BJ, Kem-
per M, Allen TM, Gretch DR, Rosen HR. Tim-3 expression on PD-1C
HCV-specific human CTLs is associated with viral persistence, and its
blockade restores hepatocyte-directed in vitro cytotoxicity. J Clin
Invest 2010; 120:4546-57; PMID:21084749; http://dx.doi.org/10.1172/
JCI43127
20. Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, Wunderlich JR,
Mixon A, Farid S, Dudley ME et al. PD-1 identifies the patient-specific
CD8 tumor-reactive repertoire infiltrating human tumors. J Clin
Invest 2014; 124:2246-59; PMID:24667641; http://dx.doi.org/10.1172/
JCI73639
21. Duraiswamy J, Ibegbu CC, Masopust D, Miller JD, Araki K,
Doho GH, Tata P, Gupta S, Zilliox MJ, Nakaya HI et al. Pheno-
type, function, and gene expression profiles of programmed
death-1(hi) CD8 T cells in healthy human adults. J Immunol
2011; 186:4200-12; PMID:21383243; http://dx.doi.org/10.4049/
jimmunol.1001783
22. Baitsch L, Legat A, Barba L, Fuertes Marraco SA, Rivals JP, Baum-
gaertner P, Christiansen-Jucht C, Bouzourene H, Rimoldi D, Pircher
H et al. Extended co-expression of inhibitory receptors by human
CD8 T-cells depending on differentiation, antigen-specificity and ana-
tomical localization. PLoS One 2012; 7:30852; PMID:22347406;
http://dx.doi.org/10.1371/journal.pone.0030852
23. Legat A, Speiser DE, Pircher H, Zehn D, Fuertes Marraco SA. Inhibi-
tory Receptor Expression Depends More Dominantly on Differentia-
tion and Activation than “Exhaustion” of Human CD8 T Cells. Front
Immunol 2013; 4:455; PMID:24391639; http://dx.doi.org/10.3389/
fimmu.2013.00455
24. Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I,
Kobayashi SV, Linsley PS, Thompson CB, Riley JL. CTLA-4 and PD-1
receptors inhibit T-cell activation by distinct mechanisms. Mol Cell
Biol 2005; 25:9543-53; PMID:16227604; http://dx.doi.org/10.1128/
MCB.25.21.9543-9553.2005
25. Kane LP, Weiss A. The PI-3 kinase/Akt pathway and T cell activation:
pleiotropic pathways downstream of PIP3. Immunol Rev 2003; 192:7-20;
PMID:12670391; http://dx.doi.org/10.1034/j.1600-065X.2003.00008.x
ONCOIMMUNOLOGY e1114203-13
26. Finlay D, Cantrell DA. Metabolism, migration and memory in cyto-
toxic T cells. Nat Rev Immunol 2011; 11:109-17; PMID:21233853;
http://dx.doi.org/10.1038/nri2888
27. Kim EH, Suresh M. Role of PI3K/Akt signaling in memory CD8 T cell
differentiation. Front Immunol 2013; 4:20; PMID:23378844; http://dx.
doi.org/10.3389/fimmu.2013.00020
28. Henson SM, Franzese O, Macaulay R, Libri V, Azevedo RI, Kiani-Ali-
khan S, Plunkett FJ, Masters JE, Jackson S, Griffiths SJ et al. KLRG1
signaling induces defective Akt (ser473) phosphorylation and prolifer-
ative dysfunction of highly differentiated CD8C T cells. Blood 2009;
113:6619-28; PMID:19406987; http://dx.doi.org/10.1182/blood-2009-
01-199588
29. Macintyre AN, Finlay D, Preston G, Sinclair LV, Waugh CM, Tamas P,
Feijoo C, Okkenhaug K, Cantrell DA. Protein kinase B controls tran-
scriptional programs that direct cytotoxic T cell fate but is dispensable
for T cell metabolism. Immunity 2011; 34:224-36; PMID:21295499;
http://dx.doi.org/10.1016/j.immuni.2011.01.012
30. Ding ZC, Huang L, Blazar BR, Yagita H, Mellor AL, Munn DH, Zhou
G. Polyfunctional CD4C T cells are essential for eradicating advanced
B-cell lymphoma after chemotherapy. Blood 2012; 120:2229-39;
PMID:22859605; http://dx.doi.org/10.1182/blood-2011-12-398321
31. Graw F, Regoes RR. Predicting the impact of CD8C T cell polyfunc-
tionality on HIV disease progression. J Virol 2014; 88:10134-45;
PMID:24965450; http://dx.doi.org/10.1128/JVI.00647-14
32. Chiu YL, Shan L, Huang H, Haupt C, Bessell C, Canaday DH, Zhang
H, Ho YC, Powell JD, Oelke M et al. Sprouty-2 regulates HIV-specific
T cell polyfunctionality. J Clin Invest 2014; 124:198-208;
PMID:24292711; http://dx.doi.org/10.1172/JCI70510
33. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ,
Hoff ST, Andersen P, Reed SG, Morris SL et al. Multifunctional TH1
cells define a correlate of vaccine-mediated protection against Leish-
mania major. Nat Med 2007; 13:843-50; PMID:17558415; http://dx.
doi.org/10.1038/nm1592
34. McKee MD, Roszkowski JJ, Nishimura MI. T cell avidity and tumor
recognition: implications and therapeutic strategies. J Transl Med
2005; 3:35; PMID:16174302; http://dx.doi.org/10.1186/1479-5876-3-
35
35. Yi JS, Cox MA, Zajac AJ. T-cell exhaustion: characteristics, causes and
conversion. Immunology 2010; 129:474-81; PMID:20201977; http://
dx.doi.org/10.1111/j.1365-2567.2010.03255.x
36. Henson SM, Macaulay R, Franzese O, Akbar AN. Reversal of func-
tional defects in highly differentiated young and old CD8 T cells by
PDL blockade. Immunology 2012; 135:355-63; PMID:22211948;
http://dx.doi.org/10.1111/j.1365-2567.2011.03550.x
37. Voehringer D, Koschella M, Pircher H. Lack of proliferative capacity
of human effector and memory T cells expressing killer cell lectinlike
receptor G1 (KLRG1). Blood 2002; 100:3698-702; PMID:12393723;
http://dx.doi.org/10.1182/blood-2002-02-0657
38. Ito T, YangM,Wang YH, Lande R, Gregorio J, Perng OA, Qin XF, Liu YJ,
GillietM. Plasmacytoid dendritic cells prime IL-10-producing T regulatory
cells by inducible costimulator ligand. J Exp Med 2007; 204:105-15;
PMID:17200410; http://dx.doi.org/10.1084/jem.20061660
39. Zheng J, Chan PL, Liu Y, Qin G, Xiang Z, Lam KT, Lewis DB, Lau YL,
Tu W. ICOS regulates the generation and function of human CD4C
Treg in a CTLA-4 dependent manner. PLoS One 2013; 8:82203;
PMID:24312642; http://dx.doi.org/10.1371/journal.pone.0082203
40. Martin-Orozco N, Li Y, Wang Y, Liu S, Hwu P, Liu YJ, Dong C, Rad-
vanyi L. Melanoma cells express ICOS ligand to promote the activa-
tion and expansion of T-regulatory cells. Cancer Res 2010; 70:9581-
90; PMID:21098714; http://dx.doi.org/10.1158/0008-5472.CAN-10-
1379
41. Badr G, Bedard N, Abdel-Hakeem MS, Trautmann L, Willems B, Vil-
leneuve JP, Haddad EK, Sekaly RP, Bruneau J, Shoukry NH. Early
interferon therapy for hepatitis C virus infection rescues polyfunc-
tional, long-lived CD8C memory T cells. J Virol 2008; 820:10017-31;
PMID:18667516; http://dx.doi.org/10.1128/JVI.01083-08
42. Almeida JR, Price DA, Papagno L, Arkoub ZA, Sauce D, Born-
stein E, Asher TE, Samri A, Schnuriger A, Theodorou I et al.
Superior control of HIV-1 replication by CD8C T cells is reflected
by their avidity, polyfunctionality, and clonal turnover. J Exp Med
2007; 204:2473-85; PMID:17893201; http://dx.doi.org/10.1084/
jem.20070784
43. Janbazian L, Price DA, Canderan G, Filali-Mouhim A, Asher TE,
Ambrozak DR, Scheinberg P, Boulassel MR, Routy JP, Koup RA et al.
Clonotype and repertoire changes drive the functional improvement
of HIV-specific CD8 T cell populations under conditions of limited
antigenic stimulation. J Immunol 2012; 188:1156-67;
PMID:22210916; http://dx.doi.org/10.4049/jimmunol.1102610
44. Darrah PA1, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn
BJ, Hoff ST, Andersen P, Reed SG, Morris SL et al. Multifunctional
TH1 cells define a correlate of vaccine-mediated protection against
Leishmania major. Nat Med 2007; 13:843-50; PMID:17558415; http://
dx.doi.org/10.1038/nm1592
45. Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, Ritter E, Ku GY, Jung-
bluth AA, Segal NH, Rasalan TS et al. CTLA-4 blockade enhances pol-
yfunctional NY-ESO-1 specific T cell responses in metastatic
melanoma patients with clinical benefit. Proc Natl Acad Sci U S A
2008; 105:20410-20415; PMID:19074257; http://dx.doi.org/10.1073/
pnas.0810114105
46. Ayyoub M, Dojcinovic D, Pignon P, Raimbaud I, Schmidt J, Luescher
I, Valmori D. Monitoring of NY-ESO-1 specific CD4C T cells using
molecularly defined MHC class II/His-tag-peptide tetramers. Proc
Natl Acad Sci U S A 2010; 107:7437-7442; PMID:20368442; http://dx.
doi.org/10.1073/pnas.1001322107
47. Kim EH, Sullivan JA, Plisch EH, Tejera MM, Jatzek A, Choi KY,
Suresh M. Signal integration by Akt regulates CD8 T cell effector and
memory differentiation. J Immunol 2012; 188:4305-14; PMID:
22467649; http://dx.doi.org/10.4049/jimmunol.1103568
48. van der Waart AB, van de Weem NM, Maas F, Kramer CS, Kester
MG, Falkenburg JH, Schaap N, Jansen JH, van der Voort R, Gattinoni
L et al. Inhibition of Akt signaling promotes the generation of superior
tumor-reactive T cells for adoptive immunotherapy. Blood 2014;
124:3490-500; PMID:25336630; http://dx.doi.org/10.1182/blood-
2014-05-578583
49. Crompton JG, Sukumar M, Roychoudhuri R, Clever D, Gros A, Eil
RL, Tran E, Hanada K, Yu Z, Palmer DC, Kerkar SP, Michalek RD
et al. Akt inhibition enhances expansion of potent tumor-specific lym-
phocytes with memory cell characteristics. Cancer Res 2015; 75:296-
305; PMID:25432172; http://dx.doi.org/10.1158/0008-5472.CAN-14-
2277
50. Abu Eid R, Friedman KM, Mkrtichyan M, Walens A, King W, Janik J,
Khleif SN. Akt1 and -2 inhibition diminishes terminal differentiation
and enhances central memory CD8C T-cell proliferation and survival.
Oncoimmunology 2015; 4:1005448; PMID:26155399; http://dx.doi.
org/10.1080/2162402X.2015.1005448
51. Bukczynski J, Wen T, Watts TH. Costimulation of human CD28- T
cells by 4-1BB ligand. Eur J Immunol 2003; 33:446-54; PMID:
12645943; http://dx.doi.org/10.1002/immu.200310020
52. Waldmann TA. The biology of interleukin-2 and interleukin-15: impli-
cations for cancer therapy and vaccine design. Nat Rev Immunol 2006;
6:595-601; PMID:16868550; http://dx.doi.org/10.1038/nri1901
53. Arimura Y, Kato H, Dianzani U, Okamoto T, Kamekura S, Buonfiglio
D, Miyoshi-Akiyama T, Uchiyama T, Yagi J. A co-stimulatory mole-
cule on activated T cells, H4/ICOS, delivers specific signals in T(h)
cells and regulates their responses. Int Immunol 2002; 14:555-66;
PMID:12039907; http://dx.doi.org/10.1093/intimm/dxf022
54. Takahashi N, Matsumoto K, Saito H, Nanki T, Miyasaka N, Kobata T,
Azuma M, Lee SK, Mizutani S, Morio T. Impaired CD4 and CD8
effector function and decreased memory T cell populations in ICOS-
deficient patients. J Immunol 2009; 182:5515-27; PMID:19380800;
http://dx.doi.org/10.4049/jimmunol.0803256
55. Wang J, He M, Shi W, Sha H, Feng J, Wang S, Wang Y. Inducible cos-
timulator (ICOS) enhances the cytolytic activity of cytokine-induced
killer cells against gallbladder cancer in vitro and in vivo. Cancer
Invest 2009; 27:244-50; PMID:19194830; http://dx.doi.org/10.1080/
07357900802239124
56. Fan X, Quezada SA, Sepulveda MA, Sharma P, Allison JP. Engage-
ment of the ICOS pathway markedly enhances efficacy of CTLA-4
blockade in cancer immunotherapy. J Exp Med 2014; 211:715-25;
PMID:24687957; http://dx.doi.org/10.1084/jem.20130590
e1114203-14 O. FRANZESE ET AL.
57. Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T. A rheostat for
immune responses: the unique properties of PD-1 and their advan-
tages for clinical application. Nat Immunol 2013; 14:1212-8;
PMID:24240160; http://dx.doi.org/10.1038/ni.2762
58. Zitvogel L, Kroemer G. Targeting PD-1/PD-L1 interactions for cancer
immunotherapy. Oncoimmunology 2012; 1:1223-1225; PMID:
23243584; http://dx.doi.org/10.4161/onci.21335
59. Aranda F, Vacchelli E, Eggermont A, Galon J, Fridman WH, Zitvogel
L, Kroemer G, Galluzzi L. Trial Watch: Immunostimulatory monoclo-
nal antibodies in cancer therapy. Oncoimmunology 2014; 3:27297;
http://dx.doi.org/10.4161/onci.27297
60. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharf-
man WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD et al. Sur-
vival, durable tumor remission, and long-term safety in patients with
advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32:1020-30;
PMID:24590637; http://dx.doi.org/10.1200/JCO.2013.53.0105
61. Caporali S, Levati L, Starace G, Ragone G, Bonmassar E, Alvino E,
D’Atri S. AKT is activated in an ataxia-telangiectasia and Rad3-related-
dependent manner in response to temozolomide and confers protec-
tion against drug-induced cell growth inhibition. Mol Pharmacol 2008;
74:173-83; PMID:18413665; http://dx.doi.org/10.1124/mol.107.044743
62. Arico E, Belardelli F. Interferon-a as antiviral and antitumor vaccine
adjuvants: mechanisms of action and response signature. J Interferon
Cytokine Res 2012; 32:235-47; PMID:22490303; http://dx.doi.org/
10.1089/jir.2011.0077
63. Daniotti M, Oggionni M, Ranzani T, Vallacchi V, Campi V, Di Stasi
D, Torre GD, Perrone F, Luoni C, Suardi S et al. BRAF alterations are
associated with complex mutational profiles in malignant melanoma.
Oncogene 2004; 23:5968-77; PMID:15195137; http://dx.doi.org/
10.1038/sj.onc.1207780
64. Nistico P1, Mortarini R, De Monte LB, Mazzocchi A, Mariani M,
Malavasi F, Parmiani G, Natali PG, Anichini A. Cell retargeting
by bispecific monoclonal antibodies. Evidence of bypass of
intratumor susceptibility to cell lysis in human melanoma.
J Clin Invest 1992; 90:1093-9; PMID:1387883; http://dx.doi.org/
10.1172/JCI1-15925
65. L€ovgren T, Baumgaertner P, Wieckowski S, Deve^vre E, Guillaume P,
Luescher I, Rufer N, Speiser DE. Enhanced cytotoxicity and decreased
CD8 dependence of human cancer-specific cytotoxic T lymphocytes
after vaccination with low peptide dose. Cancer Immunol Immun-
other 2012; 61:817-26; PMID:22080404; http://dx.doi.org/10.1007/
s00262-011-1140-1
ONCOIMMUNOLOGY e1114203-15
